ZYNEX INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ZYNEX INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $192.35M | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $184.32M | Jul 24, 2025 |
| FY2022 | Dec 31, 2022 | $48.81M | Mar 14, 2023 |
| FY2022 | Sep 30, 2022 | $41.52M | Mar 14, 2023 |
| FY2022 | Jun 30, 2022 | $36.76M | Mar 14, 2023 |
| FY2022 | Mar 31, 2022 | $31.08M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $40.37M | Mar 14, 2023 |
| FY2022 | Sep 30, 2021 | $34.79M | Mar 14, 2023 |
| FY2022 | Jun 30, 2021 | $31.02M | Mar 14, 2023 |
| FY2022 | Mar 31, 2021 | $24.13M | Mar 14, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $8.13M | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $6.82M | Feb 28, 2018 |
| FY2017 | Jun 30, 2017 | $5.04M | Feb 28, 2018 |
| FY2017 | Mar 31, 2017 | $3.44M | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $2.92M | Feb 28, 2018 |
| FY2017 | Sep 30, 2016 | $3.63M | Feb 28, 2018 |
| FY2017 | Jun 30, 2016 | $3.29M | Feb 28, 2018 |
| FY2017 | Mar 31, 2016 | $3.48M | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $11.64M | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $11.12M | Mar 31, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $13.54M | Mar 28, 2014 |
| FY2012 | Dec 31, 2012 | $30.90M | Mar 28, 2013 |
| FY2011 | Dec 31, 2011 | $26.78M | Mar 28, 2012 |
| FY2011 | Dec 31, 2010 | $18.88M | Mar 28, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.99M | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $9.73M | Jul 24, 2025 |
| FY2022 | Dec 31, 2022 | $7.45M | Mar 14, 2023 |
| FY2022 | Sep 30, 2022 | $4.87M | Mar 14, 2023 |
| FY2022 | Jun 30, 2022 | $3.35M | Mar 14, 2023 |
| FY2022 | Mar 31, 2022 | $1.38M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $8.89M | Mar 14, 2023 |
| FY2022 | Sep 30, 2021 | $6.11M | Mar 14, 2023 |
| FY2022 | Jun 30, 2021 | $2.81M | Mar 14, 2023 |
| FY2022 | Mar 31, 2021 | ($706.0K) | Mar 14, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.99M | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $10.78M | Jul 24, 2025 |
| FY2022 | Dec 31, 2022 | $10.11M | Mar 14, 2023 |
| FY2022 | Sep 30, 2022 | $6.56M | Mar 14, 2023 |
| FY2022 | Jun 30, 2022 | $4.36M | Mar 14, 2023 |
| FY2022 | Mar 31, 2022 | $1.91M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $11.59M | Mar 14, 2023 |
| FY2022 | Sep 30, 2021 | $8.05M | Mar 14, 2023 |
| FY2022 | Jun 30, 2021 | $3.81M | Mar 14, 2023 |
| FY2022 | Mar 31, 2021 | ($1.08M) | Mar 14, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $12.00M | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $9.20M | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $7.10M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $2.60M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $800.0K | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $600.0K | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $200.0K | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $100.0K | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $300.0K | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $256.0K | Apr 17, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $15.51M | Feb 26, 2019 |
| FY2018 | Dec 31, 2017 | $9.67M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $9.16M | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $9.19M | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $11.40M | Mar 31, 2016 |
| FY2014 | Dec 31, 2013 | $21.14M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $28.16M | Mar 28, 2014 |
| FY2012 | Dec 31, 2011 | $23.68M | Mar 28, 2013 |
| FY2011 | Dec 31, 2010 | $17.32M | Mar 28, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $12.72M | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $17.76M | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $13.75M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $6.95M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $818.0K | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $6.30M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $9.41M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $8.26M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $1.77M | Feb 28, 2018 |
| FY2013 | Dec 31, 2013 | ($382.0K) | Mar 28, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $578.0K | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $1.21M | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $418.0K | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $609.0K | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $985.0K | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $160.0K | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.08M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $87.0K | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $226.0K | Feb 28, 2018 |
| FY2014 | Dec 31, 2014 | $272.0K | Mar 31, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $122.08M | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $136.90M | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $116.47M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $133.27M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $72.18M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $28.28M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $19.25M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $8.93M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $4.09M | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $3.70M | Apr 17, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $86.37M | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $90.78M | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $50.11M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $59.35M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $15.32M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $8.62M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $9.96M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $4.03M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $7.89M | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $7.77M | Apr 17, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $35.71M | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $46.13M | Jul 24, 2025 |
| FY2024 | Dec 31, 2022 | $66.36M | Jul 24, 2025 |
| FY2023 | Dec 31, 2021 | $73.93M | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $56.86M | Mar 14, 2023 |
| FY2020 | Dec 31, 2019 | $19.74M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $9.38M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $4.99M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($3.71M) | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | ($3.98M) | Apr 17, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $20.40M | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $20.40M | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $20.40M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $20.40M | Mar 14, 2023 |
| FY2024 | Dec 22, 2021 | $20.40M | Jul 24, 2025 |
| FY2013 | Dec 31, 2012 | $251.0K | Mar 28, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $29.77M | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $26.78M | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $17.05M | Mar 12, 2024 |
| FY2021 | Dec 31, 2020 | $23.43M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $14.36M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $4.86M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($2.41M) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($9.78M) | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | ($9.85M) | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | ($6.93M) | Mar 31, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $5.29M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $10.61M | Mar 14, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Apr 17, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Apr 17, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 31.88M | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | 32.93M | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | 36.83M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 39.74M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 38.24M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | 32.79M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 32.27M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 32.78M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 31.27M | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | 31.27M | Apr 17, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $9.0K | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $3.0K | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $3.61M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $1.0K | Mar 14, 2023 |
| FY2020 | Dec 31, 2019 | $2.26M | Feb 25, 2021 |